Clinuvel Pharmaceuticals Ltd
ASX:CUV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd
Total Liabilities & Equity
Clinuvel Pharmaceuticals Ltd
Total Liabilities & Equity Peer Comparison
IMM
MSB
CSL
TLX
PYC
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Liabilities & Equity
AU$211.7m
|
CAGR 3-Years
34%
|
CAGR 5-Years
36%
|
CAGR 10-Years
32%
|
|
|
Immutep Ltd
ASX:IMM
|
Total Liabilities & Equity
AU$123.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
14%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities & Equity
$670.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities & Equity
$37.3B
|
CAGR 3-Years
28%
|
CAGR 5-Years
26%
|
CAGR 10-Years
20%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities & Equity
AU$398.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities & Equity
AU$39.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
29%
|
CAGR 10-Years
18%
|
See Also
What is Clinuvel Pharmaceuticals Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
211.7m
AUD
Based on the financial report for Dec 31, 2023, Clinuvel Pharmaceuticals Ltd's Total Liabilities & Equity amounts to 211.7m AUD.
What is Clinuvel Pharmaceuticals Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
32%
Over the last year, the Total Liabilities & Equity growth was 32%. The average annual Total Liabilities & Equity growth rates for Clinuvel Pharmaceuticals Ltd have been 34% over the past three years , 36% over the past five years , and 32% over the past ten years .
You don't have any saved screeners yet
